Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkmate 143 phase 3 randomized clinical trial

This randomized clinical trial examines the effect of programmed cell death 1 immune checkpoint inhibition with nivolumab on overall survival for patients with recurrent glioblastoma.

Saved in:

Bibliographic Details
Main Authors:	Reardon, David A. (Author) , Brandes, Alba A. (Author) , Omuro, Antonio (Author) , Mulholland, Paul (Author) , Lim, Michael (Author) , Wick, Antje (Author) , Baehring, Joachim (Author) , Ahluwalia, Manmeet S. (Author) , Roth, Patrick (Author) , Bähr, Oliver (Author) , Phuphanich, Surasak (Author) , Sepulveda, Juan Manuel (Author) , De Souza, Paul (Author) , Sahebjam, Solmaz (Author) , Carleton, Michael (Author) , Tatsuoka, Kay (Author) , Taitt, Corina (Author) , Zwirtes, Ricardo (Author) , Sampson, John (Author) , Weller, Michael (Author)
Format:	Article (Journal)
Language:	English
Published:	May 21, 2020
In:	JAMA oncology Year: 2020, Volume: 6, Issue: 7, Pages: 1003-1010
ISSN:	2374-2445
DOI:	10.1001/jamaoncol.2020.1024
Online Access:	Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1001/jamaoncol.2020.1024 Verlag, lizenzpflichtig, Volltext: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243167/
Author Notes:	David A. Reardon, MD; Alba A. Brandes, MD; Antonio Omuro, MD; Paul Mulholland, PhD; Michael Lim, MD; Antje Wick, MD; Joachim Baehring, MD; Manmeet S. Ahluwalia, MD; Patrick Roth, MD; Oliver Bähr, MD; Surasak Phuphanich, MD; Juan Manuel Sepulveda, MD, PhD; Paul De Souza, MD; Solmaz Sahebjam, MD; Michael Carleton, PhD; Kay Tatsuoka, PhD; Corina Taitt, MD; Ricardo Zwirtes, MD; John Sampson, MD; Michael Weller, MD

Description
Summary:	This randomized clinical trial examines the effect of programmed cell death 1 immune checkpoint inhibition with nivolumab on overall survival for patients with recurrent glioblastoma.
Item Description:	Gesehen am 06.11.2020
Physical Description:	Online Resource
ISSN:	2374-2445
DOI:	10.1001/jamaoncol.2020.1024